WallStSmart
VRDN

Viridian Therapeutics Inc

NASDAQ: VRDN · HEALTHCARE · BIOTECHNOLOGY

$13.30
-2.28% today

Updated 2026-04-29

Market cap
$1.37B
P/E ratio
P/S ratio
19.35x
EPS (TTM)
$-3.32
Dividend yield
52W range
$12 – $34
Volume
2.3M

WallStSmart proprietary scores

35
out of 100
Grade: D
Sell
Investment rating
8.0
Growth
A
7.3
Quality
B+
2.5
Profitability
F
5.0
Valuation
C+
3/9
Piotroski F-Score
Weak
3.5
Altman Z-Score
Safe zone
Industry rank
View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target
$33.56
+152.33%
12-Month target
Intrinsic (DCF)
Margin of safety
3 Strong Buy14 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths
+ Altman Z 3.53 — safe zone
+ Revenue growth 83.30% QoQ
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-23.99M

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$1.77M$314000.00$302000.00$70.85M$70.85M
Net income$-129.87M$-237.73M$-269.95M$-342.60M$-120.36M
EPS$-3.32
Free cash flow$-94.64M$-185.07M$-232.83M$-276.89M$-23.99M
Profit margin-7,329.23%-75,711.46%-89,387.09%-483.57%

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
VRDN$1.37B358.02.55.07.3Hold
LLY$789.69B7810.010.05.06.5Strong Buy
JNJ$547.64B594.79.03.36.0-41.97%Buy
ABBV$351.47B634.08.04.75.0-24.92%Buy
UNH$322.34B545.35.57.34.8+42.06%Buy
AZN$294.17B646.78.05.35.0+4.07%Buy

Smart narrative

Viridian Therapeutics Inc trades at $13.30. Our Smart Value Score of 35/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 3.53, it sits in the safe zone. TTM revenue stands at $70.85M.

Frequently asked questions

What is Viridian Therapeutics Inc's stock price?
Viridian Therapeutics Inc (VRDN) trades at $13.30.
Is Viridian Therapeutics Inc overvalued?
Smart Value Score 35/100 (Grade D, Sell).
What is the price target of Viridian Therapeutics Inc (VRDN)?
The analyst target price is $33.56, representing +152.3% upside from the current price of $13.30.
What is Viridian Therapeutics Inc's revenue?
TTM revenue is $70.85M.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
3.53 — safe zone.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio19.35x
ROE-49.20%
Beta1.17
50D MA$22.68
200D MA$24.36
Shares out0.10B
Float0.10B
Short ratio
Avg volume2.3M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years